CN110114065A - 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生 - Google Patents

通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生 Download PDF

Info

Publication number
CN110114065A
CN110114065A CN201780073942.4A CN201780073942A CN110114065A CN 110114065 A CN110114065 A CN 110114065A CN 201780073942 A CN201780073942 A CN 201780073942A CN 110114065 A CN110114065 A CN 110114065A
Authority
CN
China
Prior art keywords
seq
glu glu
compound according
asp asp
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780073942.4A
Other languages
English (en)
Chinese (zh)
Inventor
P.S.洛
S.A.洛
J.尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CN110114065A publication Critical patent/CN110114065A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780073942.4A 2016-11-30 2017-11-30 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生 Pending CN110114065A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662428492P 2016-11-30 2016-11-30
US62/428,492 2016-11-30
US201762553313P 2017-09-01 2017-09-01
US62/553,313 2017-09-01
PCT/US2017/064081 WO2018102616A1 (en) 2016-11-30 2017-11-30 Fracture targeted bone regeneration through parathyroid hormone receptor stimulation

Publications (1)

Publication Number Publication Date
CN110114065A true CN110114065A (zh) 2019-08-09

Family

ID=62241919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780073942.4A Pending CN110114065A (zh) 2016-11-30 2017-11-30 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生

Country Status (10)

Country Link
US (3) US20200317745A1 (https=)
EP (1) EP3548012A4 (https=)
JP (2) JP7649624B2 (https=)
CN (1) CN110114065A (https=)
AU (1) AU2017367699B2 (https=)
BR (1) BR112019011070A2 (https=)
CA (1) CA3045458A1 (https=)
IL (1) IL266977B2 (https=)
MX (1) MX2019006189A (https=)
WO (1) WO2018102616A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021068550A1 (en) * 2019-10-10 2021-04-15 Shaanxi Micot Technology Co., Ltd. Active polypeptide compound
CN114364327A (zh) * 2019-09-12 2022-04-15 雷迪厄斯健康公司 用阿巴帕肽改善脊柱融合的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN110551201B (zh) * 2019-08-26 2020-04-28 杭州彗搏科技有限公司 一种新型骨形成蛋白2来源的环肽、制备方法及其应用
AU2021338361A1 (en) * 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures
WO2022093374A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat spinal fusions
AU2022205801A1 (en) * 2021-01-05 2023-07-13 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
US20250295725A1 (en) * 2022-01-14 2025-09-25 Purdue Research Foundation Bone targeted treatment in osteogenesis imperfecta
EP4719459A1 (en) * 2023-06-01 2026-04-08 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities
WO2025019691A1 (en) * 2023-07-19 2025-01-23 Zymeron Corporation Drug conjugates for bone marrow protection

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002610A1 (en) * 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US20050287114A1 (en) * 2003-01-06 2005-12-29 University Of Utah Research Foundation Water-soluble polymeric bone-targeting drug delivery system
US20100129341A1 (en) * 2007-04-09 2010-05-27 Joshua Sakon Fusion proteins of collagen-binding domain and parathyroid hormone
US20110142764A1 (en) * 2008-05-22 2011-06-16 Ramot At Tel-Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
CN102824647A (zh) * 2011-06-13 2012-12-19 香港中文大学 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
US20130006217A1 (en) * 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
US20150246957A1 (en) * 2012-08-28 2015-09-03 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
CN106039316A (zh) * 2016-05-03 2016-10-26 同济大学 一种基于多肽构建的成骨细胞靶向载体及其制备与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9103791A (en) * 1990-12-21 1992-07-22 Allelix Biopharmaceuticals Inc. Oxidation resistant variants of parathyroid hormone
JP4394279B2 (ja) * 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
KR101512377B1 (ko) 2006-10-03 2015-04-28 라디우스 헬쓰, 인코포레이티드 골 아나볼릭 단백질을 위한 약물 전달 방법
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
PT2662448T (pt) 2007-05-11 2017-03-29 Alexion Pharma Inc Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma
WO2014209893A2 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
CA2977812A1 (en) * 2015-03-03 2016-09-09 Radius Health, Inc. Uses of pthrp analogue in reducing fracture risk
WO2016196400A1 (en) * 2015-05-29 2016-12-08 Purdue Research Foundation Bone fracture repair by targeting of agents that promote bone healing
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002610A1 (en) * 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US20050287114A1 (en) * 2003-01-06 2005-12-29 University Of Utah Research Foundation Water-soluble polymeric bone-targeting drug delivery system
US20100129341A1 (en) * 2007-04-09 2010-05-27 Joshua Sakon Fusion proteins of collagen-binding domain and parathyroid hormone
US20110142764A1 (en) * 2008-05-22 2011-06-16 Ramot At Tel-Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
US20130006217A1 (en) * 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
CN102824647A (zh) * 2011-06-13 2012-12-19 香港中文大学 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
US20150246957A1 (en) * 2012-08-28 2015-09-03 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
CN106039316A (zh) * 2016-05-03 2016-10-26 同济大学 一种基于多肽构建的成骨细胞靶向载体及其制备与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K.MORITA等: "Enhanced initial bone regeneration with inorganic polyphosphate-adsorbed hydroxyapatite" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364327A (zh) * 2019-09-12 2022-04-15 雷迪厄斯健康公司 用阿巴帕肽改善脊柱融合的方法
WO2021068550A1 (en) * 2019-10-10 2021-04-15 Shaanxi Micot Technology Co., Ltd. Active polypeptide compound
CN114786704A (zh) * 2019-10-10 2022-07-22 陕西麦科奥特科技有限公司 活性多肽化合物
CN114786704B (zh) * 2019-10-10 2023-08-25 陕西麦科奥特科技有限公司 活性多肽化合物

Also Published As

Publication number Publication date
JP2023029957A (ja) 2023-03-07
IL266977B1 (en) 2023-09-01
AU2017367699B2 (en) 2023-12-07
WO2018102616A1 (en) 2018-06-07
AU2017367699A8 (en) 2019-07-25
US10960054B2 (en) 2021-03-30
IL266977B2 (en) 2024-01-01
MX2019006189A (es) 2019-11-18
AU2017367699A1 (en) 2019-07-11
EP3548012A1 (en) 2019-10-09
JP2020500871A (ja) 2020-01-16
RU2019119701A3 (https=) 2021-02-16
CA3045458A1 (en) 2018-06-07
US20200317745A1 (en) 2020-10-08
US20210283227A1 (en) 2021-09-16
IL266977A (en) 2019-07-31
BR112019011070A2 (pt) 2019-10-01
RU2019119701A (ru) 2021-01-14
EP3548012A4 (en) 2020-07-22
US20200316174A1 (en) 2020-10-08
JP7649624B2 (ja) 2025-03-21

Similar Documents

Publication Publication Date Title
US10960054B2 (en) Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
JP5270799B2 (ja) 副甲状腺ホルモンを低減する治療剤
BRPI0717441B1 (pt) Composto, medicamento, e, uso do derivado de metastina
JP4541899B2 (ja) ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン（ｐｔｈ）アナログ
JP4334480B2 (ja) α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン
RU2430107C2 (ru) Производные метастина и их применение
JP2026032056A (ja) ヒトトランスフェリンレセプター結合ペプチド
JP5360738B2 (ja) 細胞増殖促進活性を有するペプチド
CN112672747B (zh) 用于激活骨祖细胞中细胞信号传导的肽
JP5744844B2 (ja) 副甲状腺ホルモン（ｐｔｈ）受容体アゴニストとしての短鎖ペプチド
KR101108354B1 (ko) Ｐｔｈ 수용체 조절제로서의 페길화된 ｐｔｈ 및 그의 용도
US20230390363A1 (en) Compounds, Compositions and Methods of Use to Treat Spinal Fusions
WO2017073764A1 (ja) 新規ｎｋ３受容体アゴニスト
KR102520348B1 (ko) 페길화 생활성 펩타이드 및 그의 용도
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
RU2785401C2 (ru) Направленная регенерация переломанной кости посредством стимуляции рецептора паратиреоидного гормона
US20090042802A1 (en) Compounds and peptides that bind the kgf receptor
RU2454425C2 (ru) Производные метастина и их применение
HK40050388B (zh) 用於激活骨祖细胞中细胞信号传导的肽
HK40050388A (en) Peptides for activation of cell signaling in osteoprogenitor cells
TW200817439A (en) PTH receptor modulators and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination